Locations:
Search IconSearch

Multiple Sclerosis

pathology slice of human spinal cord

Unmasking Spinal Cord Pathology in MS: 7T MRI Reveals Neurodegeneration Beyond Demyelination

Novel insights from a postmortem study combining imaging, pathology and clinical perspectives

Dr. Robert Fox against a decorative background with a podcast icon overlay
April 16, 2025/Neurosciences/Podcast

Emerging Therapeutic Options in Progressive Multiple Sclerosis (Podcast)

Long-awaited efficacy against disability progression appears to be at hand

medication vials, syringes, tablets and capsules on a tabletop

Early Intensive or Escalation Therapy for Relapsing-Remitting Multiple Sclerosis?

Extension of DELIVER-MS trial will clarify long-term clinical effects of dueling treatment philosophies

hand pointing at brain scans on a computer monitoring

Disability Progression Slowed for First Time in Nonrelapsing Secondary Progressive Multiple Sclerosis

BTK inhibitor tolebrutinib shows positive results in phase 3 HERCULES trial

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

middle-aged woman with surgical mask looking out a window

Registry Studies Reassure on Impact of COVID-19 in People With MS

No effect on symptom severity or disability, and low prevalence of long COVID

Headshot of Grace Tworek
November 20, 2024/Behavioral Health/Podcasts

Navigating Behavioral Health Challenges in Patients With Multiple Sclerosis (Podcast)

Using multidisciplinary care to address mood changes, mitigate daily stressors

3D maps of T2 MRIs in postmortem multiple sclerosis brains

Disability Can Be Independent of Cerebral White Matter Demyelination in Progressive MS

MRI classifier identifies a subset of patients with disease marked by cortical atrophy, not demyelination

dr. daniel ontaneda against a decorative background
October 2, 2024/Neurosciences/Podcast

Takeaways From the New Diagnostic Criteria for Multiple Sclerosis (Podcast)

A co-author explains some of the key McDonald criteria revisions

middle-aged woman leaning against porch railing

First Evidence of Delayed Disability Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis

The BTK inhibitor tolebrutinib meets its primary endpoint in phase 3 HERCULES trial

Hersh, MD

Let’s Move From Categorizing MS by Clinical Phenotype to Underlying Disease Mechanisms

Meaningful characterization is critical to advancing research and care, review authors contend

BackPage 1 of 5Next

Advertisement

Ad